SEC Filing Summary: AIKIDO PHARMA INC. (AIKI)
Business Context and Reporting Period
This Form 8-K was filed by AIKIDO PHARMA INC. on August 10, 2021. The registrant is a Delaware corporation with its principal executive offices in New York, NY. The filing addresses a regulatory notice regarding the continued listing of its common stock on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a listing compliance issue rather than financial performance metrics.
Material Changes
On August 10, 2021, the Company received a deficiency notice from Nasdaq stating that its common stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This non-compliance was based on the closing bid price during the period from June 28, 2021, to August 9, 2021.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted a 180-calendar-day compliance period, ending on February 7, 2022, to regain compliance.
- Regaining Compliance: To satisfy the requirement, the closing bid price of the common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to February 7, 2022.
- Risk of Delisting: Failure to meet the minimum bid price requirement within the compliance period may result in the delisting of the Company's common stock from The Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current trading price of AIKI stock to assess proximity to the $1.00 threshold.
- Monitor the stock's closing bid price daily to track progress toward the 10 consecutive business days requirement.
- Review subsequent filings for any updates on the Company's plan to regain compliance or potential reverse stock split announcements.
- Confirm the exact deadline of February 7, 2022, for the final compliance determination.